nika pharmaceuticals inc - NIKA

NIKA

Close Chg Chg %
0.32 0.08 25.59%

Open Market

0.40

+0.08 (25.59%)

Volume: 2.92K

Last Updated:

Apr 24, 2026, 12:31 PM EDT

Company Overview: nika pharmaceuticals inc - NIKA

NIKA Key Data

Open

$0.30

Day Range

0.30 - 0.40

52 Week Range

0.25 - 0.96

Market Cap

$419.02M

Shares Outstanding

1.05B

Public Float

117.96M

Beta

39.39

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

$0.00

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

588.14

 

NIKA Performance

1 Week
 
0.00%
 
1 Month
 
5.79%
 
3 Months
 
43.57%
 
1 Year
 
-52.59%
 
5 Years
 
N/A
 

NIKA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About nika pharmaceuticals inc - NIKA

Nika Pharmaceuticals, Inc. engages in the development and distribution of a variety of pharmaceutical products, including dietary supplements and antiviral drugs. Its products include veterinary medicinal products, plant protection products, other dietary supplements, and generic drugs. The company was founded on June 8, 2000 and is headquartered in Henderson, NV.

NIKA At a Glance

Nika Pharmaceuticals, Inc.
2269 Merrimack Valley Avenue
Henderson, Nevada 89044
Phone 1-702-326-3615 Revenue 0.00
Industry Pharmaceuticals: Other Net Income -76,398.00
Sector Health Technology Employees N/A
Fiscal Year-end 12 / 2026
View SEC Filings

NIKA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -5,211.689
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

NIKA Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover N/A
Total Asset Turnover N/A

NIKA Liquidity

Current Ratio 0.066
Quick Ratio 0.066
Cash Ratio 0.006

NIKA Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -392.489
Return on Equity N/A
Return on Total Capital 25.669
Return on Invested Capital N/A

NIKA Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Nika Pharmaceuticals Inc - NIKA

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
- - - -
-
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- - - -
-
Depreciation
- - - -
-
Amortization of Intangibles
- - - -
-
COGS Growth
- - - -
-
Gross Income
- - - -
-
Gross Income Growth
- - - -
-
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
3.18M 64.83K 95.79K 76.40K
Research & Development
- - - 3.00M
-
Other SG&A
183.72K 64.83K 95.79K 76.40K
SGA Growth
+21,540.26% -97.96% +47.75% -20.25%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(3.18M) (64.83K) (95.79K) (76.40K)
Non Operating Income/Expense
- - - -
-
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(3.18M) (64.83K) (95.79K) (76.40K)
Pretax Income Growth
-21,540.26% +97.96% -47.75% +20.25%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(3.18M) (64.83K) (95.79K) (76.40K)
Minority Interest Expense
- - - -
-
Net Income
(3.18M) (64.83K) (95.79K) (76.40K)
Net Income Growth
-21,540.26% +97.96% -47.75% +20.25%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(3.18M) (64.83K) (95.79K) (76.40K)
Preferred Dividends
- - - -
-
Net Income Available to Common
(3.18M) (64.83K) (95.79K) (76.40K)
EPS (Basic)
-0.0036 -0.0001 -0.0001 -0.0001
EPS (Basic) Growth
- - -620.00% +97.22%
-
Basic Shares Outstanding
876.09M 876.09M 1.02B 1.05B
EPS (Diluted)
-0.0036 -0.0001 -0.0001 -0.0001
EPS (Diluted) Growth
- - -620.00% +97.22%
-
Diluted Shares Outstanding
876.09M 876.09M 1.02B 1.05B
EBITDA
(3.18M) (64.83K) (95.79K) (76.40K)
EBITDA Growth
-21,543.24% +97.96% -47.76% +20.24%
EBITDA Margin
- - - -
-

Nika Pharmaceuticals Inc in the News